Mairead Murphy's research while affiliated with Trinity College Dublin and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (4)
Autoantibodies represent an attractive biomarker for diagnostic assays principally due to the stability of immunoglobulin in patient serum facilitating measurement with conventional assays. Immune responses to tumorigenesis may facilitate detection of ovarian cancer in the early stages of the disease with identification of a panel of tumour specifi...
One of the deadly hallmarks of cancer is its ability to prosper within the constraints of the host immune system. Recent advances in immunoproteomics and high-throughput technologies have lead to profiling of the antibody repertoire in cancer patients. This in turn has lead to the identification of tumour associated antigens/autoantibodies. Autoant...
Citations
... Very little data are currently available on the prevalence of anti-p53 antibodies in patients with epithelial ovarian cancer [16]. Murphy et al. [17] used ELISA to detect anti-p53 antibody in sera in normal heath individuals and ovarian cancer patients, however, the distribution of anti-p53 antibody in the two groups showed no significant difference. Additionally, Høgdall et al. [18] found that the frequency of anti-p53 antibodies in ovarian cancer patients increased somewhat with increasing clinical stage of disease, but the differences did not reach statistical significance. ...
![[object Object]](https://c5.rgstatic.net/m/4671872220764/images/template/default/profile/profile_default_m.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/294966342504452-1447336864334_Q64/Dolores-Cahill.jpg)
... The mutation of the P53 tumour suppressor gene is the earliest occurrence in carcinogenesis and leads to the accumulation of the P53-protein in cells. The accumulation of P53 protein activates P53 autoimmunity and subsequent production of serological anti-P53 autoantibodies (anti-P53abs) [6,8,9]. Anti-P53abs are not present in sera of healthy individuals. ...
